JILL DAVIS: Open Payments
NPI 1316330988 · LEAVENWORTH, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,105 in 107 payments from 11 companies in 2025. Trend: 2023 $1,088 · 2024 $780 · 2025 $2,105
Food & beverage: $1,994Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 20 | $313 |
| Neurocrine BioSciences, Inc. | 8 | $311 |
| Otsuka America Pharmaceutical, Inc. | 15 | $272 |
| Vanda Pharmaceuticals Inc. | 10 | $253 |
| Alkermes, Inc. | 14 | $214 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $211 |
| Teva Pharmaceuticals USA, Inc. | 7 | $184 |
| E.R. Squibb & Sons, L.L.C. | 9 | $157 |
| Janssen Pharmaceuticals, Inc | 5 | $117 |
| Lundbeck LLC | 2 | $42 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, ARISTADA, HETLIOZ, COBENFY, ABILIFY ASIMTUFII, REXULTI.
Industry payments across KS — which companies pay providers there.
